Takeda taps Wave for antisense compounds | February 26, 2018 Issue - Vol. 96 Issue 9 | Chemical & Engineering News
Volume 96 Issue 9 | p. 15 | Concentrates
Issue Date: February 26, 2018

Takeda taps Wave for antisense compounds

By Ryan Cross
Department: Business
Keywords: Neuroscience, Takeda, Wave Life Sciences, antisense, Gregory Verdine, ALS, Huntington's disease, amyotrophic lateral sclerosis

Takeda Pharmaceutical is partnering with Wave Life Sciences to develop antisense nucleic acid therapies to treat neurological conditions such as Huntington’s disease and amyotrophic lateral sclerosis. Takeda will pay $110 million in cash to Wave, purchase $60 million of Wave’s shares, and provide $60 million or more in research funding over four years. Wave’s oligonucleotides are designed to block the production of proteins that cause disease. The Harvard chemist and serial entrepreneur Gregory Verdine was one of Wave’s cofounders.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment